Structure-Based Design of Novel Thiazolone[3,2-]pyrimidine Derivatives as Potent RNase H Inhibitors for HIV Therapy.

Ribonuclease H (RNase H) was identified as an important target for HIV therapy. Currently, no RNase H inhibitors have reached clinical status. Herein, a series of novel thiazolone[3,2-]pyrimidine-containing RNase H inhibitors were developed, based on the hit compound , identified from screening our in-house compound library.